Correlation Between Karyopharm Therapeutics and Dianthus Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Dianthus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Dianthus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Karyopharm Therapeutics and Dianthus Therapeutics, you can compare the effects of market volatilities on Karyopharm Therapeutics and Dianthus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Dianthus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Dianthus Therapeutics.

Diversification Opportunities for Karyopharm Therapeutics and Dianthus Therapeutics

0.55
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Karyopharm and Dianthus is 0.55. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Dianthus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dianthus Therapeutics and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Dianthus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dianthus Therapeutics has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Dianthus Therapeutics go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Dianthus Therapeutics

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Dianthus Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 1.34 times less risky than Dianthus Therapeutics. The stock trades about -0.71 of its potential returns per unit of risk. The Dianthus Therapeutics is currently generating about -0.02 of returns per unit of risk over similar time horizon. If you would invest  2,345  in Dianthus Therapeutics on September 26, 2024 and sell it today you would lose (55.00) from holding Dianthus Therapeutics or give up 2.35% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Karyopharm Therapeutics  vs.  Dianthus Therapeutics

 Performance 
       Timeline  
Karyopharm Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.
Dianthus Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Dianthus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unsteady performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Karyopharm Therapeutics and Dianthus Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Karyopharm Therapeutics and Dianthus Therapeutics

The main advantage of trading using opposite Karyopharm Therapeutics and Dianthus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Dianthus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dianthus Therapeutics will offset losses from the drop in Dianthus Therapeutics' long position.
The idea behind Karyopharm Therapeutics and Dianthus Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Other Complementary Tools

Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Equity Valuation
Check real value of public entities based on technical and fundamental data